Olympus (7733) AI Stock Analysis

• Market Cap: ¥2.04T
• Dividend Yield: 1.1%
• Average Volume (3M): 4.97M
• Price to Earnings (P/E): 17.2
• Beta (1Y): 0.81
• Revenue Growth: 6.53%
• EPS Growth: -46.94%
• Country: JP
• Employees: 28,838
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 29.73
• Shares Outstanding: 1,139,116,300
• 10 Day Avg. Volume: 3,449,610
• 30 Day Avg. Volume: 4,965,733
• PEG Ratio: 0.41
• Price to Book (P/B): 2.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,209.29
• Price Target Upside: 21.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 76 Outperform
• Price Target: ¥2,053.00 ▲(12.99%Upside)

Olympus's strong financial performance, particularly in growth and profitability, significantly contributes to its stock score. While technical indicators suggest mixed momentum, the valuation remains reasonable, supporting a balanced investment view. The absence of earnings call data and corporate events limits further insight.

Olympus Business Overview & Revenue Model

Company Description

Olympus Corporation, headquartered in Tokyo, Japan, is a global leader in the manufacturing and distribution of precision technology products, with a focus on medical and scientific equipment. The company is renowned for its innovations in optical and digital solutions, including endoscopes, microscopes, and other advanced medical imaging technologies. Olympus serves various sectors, including healthcare, life sciences, and industrial solutions, providing tools and systems that enhance the capabilities of professionals in these fields.

How the Company Makes Money

Olympus makes money primarily through the sale of its medical systems, scientific solutions, and industrial equipment. The largest revenue stream comes from its medical business, especially the sales of endoscopic devices and related surgical equipment used in minimally invasive procedures. The company also generates revenue from its scientific solutions division, which includes microscopes and other laboratory equipment used in research and development. Additionally, Olympus has a significant presence in the industrial sector, offering products such as non-destructive testing equipment and industrial microscopes. Partnerships with hospitals, research institutions, and industrial firms contribute significantly to its earnings, alongside continuous investment in research and development to innovate and maintain its competitive edge in technology and healthcare markets.

Olympus Financial Statement Overview

Summary

Olympus exhibits strong financial health with consistent revenue growth, robust profit margins, and improving cash flow. The stability of the balance sheet and effective debt management further contribute to its solid financial position, despite some fluctuations in net income and free cash flow.

Income Statement

Olympus has demonstrated a strong revenue growth rate, with consistent annual increases culminating in a 6.52% growth in 2025. The company's gross profit margin remains robust, consistently above 67% in recent years, which indicates efficient cost management. The net profit margin improved significantly in 2025 compared to previous years. EBIT and EBITDA margins are healthy, showcasing strong operational performance. However, fluctuations in net income, particularly the drop in 2024, highlight some volatility in profitability.

Balance Sheet

The balance sheet shows a solid equity position with an improving equity ratio, reaching 52.45% in 2025, indicating financial stability. The debt-to-equity ratio decreased, reflecting effective debt management. Return on equity has been strong, though it experienced fluctuations due to varying net income levels. The company's leverage has been reduced over recent years, enhancing financial flexibility.

Cash Flow

Olympus has shown impressive growth in free cash flow, particularly in 2025, following a challenging 2024. The operating cash flow to net income ratio is favorable, indicating efficient cash generation relative to profits. The company has maintained a positive free cash flow, demonstrating strong cash management. However, the fluctuations in free cash flow highlight potential volatility in cash generation.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	997.33B	936.21B	881.92B	868.87B	730.54B
Gross Profit	683.70B	625.12B	596.85B	571.70B	459.53B
EBITDA	231.90B	112.10B	238.82B	233.16B	160.81B
Net Income	117.86B	242.57B	143.43B	115.74B	12.92B
Balance Sheet
Total Assets	1.43T	1.53T	1.51T	1.36T	1.18T
Cash, Cash Equivalents and Short-Term Investments	252.53B	340.93B	180.69B	312.84B	227.75B
Total Debt	229.10B	299.62B	340.06B	386.13B	355.26B
Total Liabilities	681.09B	777.03B	867.07B	846.64B	785.54B
Stockholders Equity	751.73B	757.19B	640.09B	510.17B	394.33B
Cash Flow
Free Cash Flow	144.46B	-22.26B	27.87B	107.96B	64.89B
Operating Cash Flow	190.46B	42.37B	98.49B	169.73B	124.12B
Investing Cash Flow	-65.47B	359.99B	-58.41B	-71.02B	-118.92B
Financing Cash Flow	-211.54B	-276.01B	-143.18B	-40.67B	40.80B

Olympus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1817.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7733, the sentiment is Positive. The current price of 1817 is above the 20-day moving average (MA) of 1693.80, above the 50-day MA of 1801.69, and below the 200-day MA of 2142.52, indicating a neutral trend. The MACD of -16.94 indicates Negative momentum. The RSI at 58.16 is Neutral, neither overbought nor oversold. The STOCH value of 73.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7733.

Olympus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6869	79 Outperform	¥1.59T	29.20	11.84%	1.17%	10.21%	8.55%
7733	76 Outperform	¥2.04T	17.23	15.47%	1.10%	6.53%	-46.94%
7741	75 Outperform	¥6.65T	31.97	20.56%	0.83%	13.56%	12.78%
4543	73 Outperform	¥3.83T	31.33	8.56%	1.00%	12.40%	10.46%
7747	72 Outperform	$643.35B	59.97	7.09%	1.02%	17.38%	-30.54%
8086	57 Neutral	¥223.20B	43.08	2.07%	2.34%	9.85%	-53.97%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%

Olympus Corporate Events

Olympus Partners with Revival Healthcare for Endoluminal Robotics Venture

Olympus Corporation has announced a joint venture with Revival Healthcare Capital to develop endoluminal robotic surgery products through Swan EndoSurgical, Inc. This strategic investment aims to strengthen Olympus’s position in the MedTech industry by capitalizing on the growing market for minimally invasive surgical solutions, with potential investments reaching up to $458 million over six years. The venture underscores Olympus’s commitment to advancing medical technology and improving patient outcomes.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Reports FY2025 Financial Results Amid Business Reorganization

Olympus has reported its financial results for FY2025, highlighting a reorganization of its business segments and the divestiture of its orthopedic business. The company recorded a gain from the sale of its Evident operation in FY2024 Q1 and anticipates further changes as it transitions its focus towards gastrointestinal and surgical solutions, impacting its financial reporting and market strategy.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Share Repurchase and Cancellation Plan

Olympus Corporation announced a strategic move to repurchase up to 36 million of its common shares, representing 3.19% of its outstanding shares, with a maximum expenditure of 50 billion yen. This decision aims to enhance shareholder returns and improve capital efficiency, with the repurchase scheduled between July and October 2025, followed by the cancellation of the repurchased shares in November 2025, excluding those allocated for stock compensation.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Reports Strong Operating Profit Amidst Strategic Restructuring

Olympus Corporation reported a significant increase in operating profit for the fiscal year ended March 31, 2025, despite a decline in total comprehensive income. The company has classified its Orthopedic Business as a discontinued operation, impacting the financial results. The forecast for the next fiscal year indicates a slight increase in revenue, but a decrease in operating profit and profit attributable to owners. The company also announced changes in its consolidation scope, including the addition of Olympus Corporation Chile and the exclusion of two other companies.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Leadership Changes to Drive Growth

Olympus Corporation announced significant leadership changes, appointing Bob White as the new Representative Executive Officer, President, and CEO, effective June 1, 2025. This decision is part of a strategic succession process aimed at driving further transformation and growth in the global MedTech sector. The appointment reflects the company’s commitment to leveraging White’s extensive experience in the medical device industry to enhance its market position and create value for stakeholders.